Resultados da pesquisa

Progression‐free and overall survival in patients with relapsed/refractory germ cell tumors treated with single‐agent chemotherapy: Endpoints for clinical trial design Por Darren R. Feldman, Sujata Patil, M. J. Trinos, Maryann Carousso, Michelle S. Ginsberg, Joel Sheinfeld, Dean F. Bajorin, George J. Bosl, Robert J. Motzer

Obter o texto integral

The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment Por Monica Fornier, P. Fumoleau

Obter o texto integral

Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones Por Dana M. Roque, Stefania Bellone, Diana P. English, Natália Buza, Emiliano Cocco, Sara Gasparrini, Ileana Bortolomai, Elena Ratner, Dan‐Arin Silasi, Masoud Azodi, Thomas Rutherford, Peter E. Schwartz, Alessandro D. Santin

Obter o texto integral Obter o texto integral

Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800) Por Robert Dreicer, Shuli Li, Judith Manola, Naomi B. Haas, Bruce J. Roth, George Wilding

Obter o texto integral Obter o texto integral

Microtubules: A dynamic target in cancer therapy Por Eddy Pasquier, Maria Kavallaris

Obter o texto integral Obter o texto integral

Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane Por Alvaro Moreno‐Aspitia, Edith A. Perez

Obter o texto integral

Systemic treatment strategies for triple-negative breast cancer Por Budhi Singh Yadav

Obter o texto integral

Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group St... Por Koen De Geest, John A. Blessing, Robert T. Morris, Shigeki Yamada, Bradley J. Monk, Susan Zweizig, Daniela Matei, Carolyn Y. Muller, William E. Richards

Obter o texto integral Obter o texto integral

Eribulin drug review Por Nishitha Shetty, Sudeep Gupta

Obter o texto integral Obter o texto integral

Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice Por Krystyna M. Wozniak, K. Nomoto, Rena G. Lapidus, Ying Wu, Valentina Carozzi, Guido Cavaletti, Kazuhiro Hayakawa, Satoru Hosokawa, Murray J. Towle, Bruce A. Littlefield, Barbara S. Slusher

Obter o texto integral Obter o texto integral

Novel microtubule-targeting agents – the epothilones Por Daniel R. Budman

Obter o texto integral Obter o texto integral

Chemotherapy in Patients with Anthracycline and Taxane-Pretreated Metastatic Breast Cancer: An Overview Por Eleni Andreopoulou, Joseph A. Sparano

Obter o texto integral

A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days Por Sen Hong Zhuang, Manish Agrawal, Maureen Edgerly, Susan Bakke, Herb Kotz, Paul Thambi, Ann Rutt, Frank M. Balis, Susan E. Bates, Tito Fojo

Obter o texto integral Obter o texto integral

<i>In vivo</i> Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer Models Por Jennifer K. Peterson, Chandra L. Tucker, Edward Favours, Pamela J. Cheshire, Jeremy Creech, Catherine A. Billups, Richard Smykla, Francis Y. F. Lee, Peter J. Houghton

Obter o texto integral Obter o texto integral

5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells Por Yongshan Yao, Shenghan Chen, Xin Zhou, Li Xie, Aijun Chen

Obter o texto integral Obter o texto integral

Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: Implications for chemotherapy-induced peripheral neu... Por Nichole E. LaPointe, Gerardo Morfini, Scott T. Brady, Stuart C. Feinstein, Leslie Wilson, Mary Ann Jordan

Obter o texto integral

Microtubule-Binding Natural Products for Cancer Therapy Por Qing‐Xi Yue, Xuan Liu, De‐an Guo

Obter o texto integral Obter o texto integral

Preclinical discovery of ixabepilone, a highly active antineoplastic agent Por Francis Y. F. Lee, R. M. Borzilleri, Craig R. Fairchild, Amrita V. Kamath, Richard Smykla, Robert A. Kramer, Gregory D. Vite

Obter o texto integral Obter o texto integral

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models Por Maria Jure–Kunkel, Gregg Masters, Emel Girit, Gennaro Dito, Francis Lee, John T. Hunt, Rachel Humphrey

Obter o texto integral Obter o texto integral

Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P Por Don S. Dizon, John A. Blessing, D. Scott McMeekin, Sudarshan Sharma, Paul DiSilvestro, Ronald D. Alvarez

Obter o texto integral Obter o texto integral